Factors associated with relapse in schizophrenia

South African Journal of Psychiatry

Volumn 14, Issue 2, 2008, Pages 52-62

  Kazadi, N J B ^a   Moosa, M Y H ^a   Jeenah, F Y ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIS; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG WITHDRAWAL; EMPLOYMENT STATUS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SELECTION; RELAPSE; RESIDENTIAL AREA; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SEX DIFFERENCE; SOUTH AFRICA; SUBSTANCE ABUSE;

EID: 48749107962     PISSN: 16089685     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajpsychiatry.v14i2.158     Document Type: Article

References (58)

1. Gelder MG, Lopez-Ibor JJ, Andreasen NC. New Oxford Textbook of Psychiatry. Oxford: Oxford University Press, 2000: 567-621.
2. Suzuki Y, Yasumura S, Fukao S, et al. Associated factors of rehospitalization among schizophrenic patients. Psychiatry Clin Neurosci 2003; 57: 555-561.
3. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346-351.
4. Piggot TA, Carson WH, Scha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26 week study. J Clin Psychiatry 2003; 64: 1048-1057.
5. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychoic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184: 509-516.
6. Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005; 79: 85-93.
7. Diagnostic and Statistical Manual of Mental Disorders - DSM-IV-TR. 4th ed. Washington DC: American Psychiatric Association, 2002.
8. Awad GA. Antipsychotic medications: compliance and attitudes towards treatment. Curr Opin Psychiatry 2004; 17: 75-80.
9. Hudson TJ, Owen RR, Trush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004; 65: 211-216.
10. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-264.
11. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-908.
12. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication adherence in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 4: 637-651.
13. Suzuki T, Uchida H, Takeuchi H, et al. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology 2005; 181: 566-575.
14. Perkins DO. Predictors of nonadherence in patients with schizophrenia. J Clin Psychiatry 2002; 63: 12-16.
15. Gillis LS, Koch A, Joyi M. Improving compliance in Xhosa psychiatric patients. S Afr Med J 1989; 76: 205-208.
16. Swofford CD, Kasckow JW, Scheller Gilkey G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996; 20: 145-151.
17. Regier DA, Farmer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drug abuses. JAMA 1990; 264: 2511-2518.
18. Salloum IM, Moss HB, Daley DC. Substance abuse and schizophrenia: impediments to optimal care. Am J Drug Alcohol Abuse 1991; 17: 321-336.
19. Solombela PW, Uys LR. Factors influencing the relapse of outpatients with schizophrenia in the Kentani area of Transkei. Curationis 1994; 17: 24-28.
20. Gillis LS, Sandler R, Jakoet A, Elk R. Readmissions to a psychiatric hospital: Outcome on follow up. S Afr Med J 1986; 70: 735-739.
21. Pourmand DD, Kavanagh DJ, Vaughan K. Expressed emotion as predictor of relapse in patients with comorbid psychoses and substance use disorder. Aust NZ J Psychiatry 2005; 39: 473-478.
22. Compton MT, Weiss PS, West JC, et al. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 939-946.
23. Murray RM, Castle DJ. Genetic and environmental risk factors for schizophrenia. In: Gelder MG, ed. Oxford Textbook of Psychiatry. Oxford: Oxford University Press, 2000.
24. Hunter PE, Storat B. Psychosocial triggers of relapse in persons with chronic mental illness: A pilot study. Ment Health Nurs 1994; 15: 67-72.
25. Mwaba K, Molamu RB. Perceived causes of relapse among a sample of recovering patients at a Mafikeng Hospital. Curationis 1998; 21: 55-57.
26. Siris SG. Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000; 157: 1379-1389.
27. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55: 250-258.
28. Hogarty GE, Ulrich RF. The limitations of anti-psychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psych Research 1998; 32: 243-250.
29. Joubert PM. Community psychiatry in South Africa. SA Psych Rev 2002; 5: 4-6.
30. Carpenter WT. Maintenance therapy of persons with schizophrenia. J Clin Psychiatry 1996; 57: 10-16.
31. Marder SR. Overview of partial adherence. J Clin Psychiatry 2003; 64: 3-9.
32. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079-1087.
33. Rosenheck RA. Outcomes, costs, and policy caution: A commentary on the cost utility of the latest antipsychotic drugs in schizophrenia study. Arch Gen Psychiatry 2006; 63: 1074-1076.
34. Lieberman JA, Scott Stroup T, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209-1223.
35. Thieda P, Beard S, Ritchter A, Kane J. An economic review of adherence with medicaiion therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-516.
36. Olfson M, Mechanic D, Hansell S, et al. Predicting medication non adherence after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51: 215-222.
37. Burton SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psych Pract 2005; 11: 369-378.
38. Razaly MS, Yahya H. Adherence with treatment in schizophrenia. A drug intervention program in a developing program. Acta Psychiatr Scandinav 1995; 91: 331-335.
39. Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222.
40. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64: 14-17.
41. Fleishhacker WW, Melse U, Gunther V, et al. Adherence with antipsychotic drug treatment: influence of side-effects. Acta Psychiatr Scand 1994; 89: 11-21.
42. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigation. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
43. Lieberman JA. Comparative effectiveness of antipsychotic drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006; 63: 1069-1072.
44. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564.
45. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526.
46. Du Preez RR, Griffith WC, Page M. Major depressive disorder as a co-morbid diagnosis in schizophrenia versus the diagnosis of schizoaffective disorder - depressed type. S Afr Psychiatry Rev 2005; 8: 134-139.
47. Elbogen EB, Swanson JW, Swartz MS, et al. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis 2005; 193: 673-679.
48. Birchwood M, Mason R, Macmillan F, et al. Depression, demoralization and control over psychotic illness a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993; 23: 387-395.
49. Robinson D, Woerner MG, Ma J, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247.
50. Margolese HC, Carlos Negrete J, Tempier R, et al. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. Schizophr Res 2006; 83: 65-75.
51. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76: 135-157.
52. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004; 55: 491-493.
53. Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: A case control study of seriously mentally ill persons in Mississipi. Am J Psychiatry 1995; 152: 1749-1752.
54. Dixon L, Haas G, Weiden P, et al. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients self-reports. Schizophr Bull 1990; 16: 69-79.
55. Warner R, Taylor D, Wright J, et al. Substance use among the mentally ill: prevalence, reasons for use, and effects on illness. Am J Orthopsychiatry 1994; 64: 30-39.
56. Fenton WS. Comorbid conditions in schizophrenia. Curr Opin Psychiatry 2001; 14: 17-23.
57. Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin N Am 2003; 26: 115-139.
58. Dolder C, Lacro J, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003; 65: 156-162.